Rafiq Ramadan, MD
Interventional Cardiology · Saint Louis, MONPI 1396769055
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Biotronik Inc. at 43.3% of the total. Reporting peaked in 2019 at $9,299 and has fallen 74.6% since, to $2,366 in 2025.
Across 791 payments — averaging $26.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$9K
- Novartis$2K
- Medtronic$985
- Boehringer Ingelheim$952
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$647
- Johnson & Johnson$641
- plus $7K from 41 others
Across 449 payments — averaging $301.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotronik Inc.$58K
- Impulse Dynamics (USA) Inc.$54K
- Boston Scientific$23K
What the payments were for
- Consulting fees$7,20034%
- Travel & lodging$1,4597%
- Food & beverage$12,56859%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$356
- OPTIMIZER SMART SYSTEM$128
- Micra$125
- Coala Heart Monitor$114
- Claria MRI$113
How this compares
$21,247 in reported general payments places this provider in the 70th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 238 | $271,204 |
| XareltoRivaroxaban | 66 | $84,277 |
| EntrestoSacubitril/Valsartan | 69 | $80,229 |
| OzempicSemaglutide | 34 | $52,819 |
| JardianceEmpagliflozin | 38 | $47,761 |
| Repatha SureclickEvolocumab | 45 | $42,859 |
| BrilintaTicagrelor | 45 | $28,446 |
| TrulicityDulaglutide | 19 | $18,948 |
| FarxigaDapagliflozin Propanediol | 16 | $14,143 |
| Dofetilide | 39 | $12,331 |
| Ranolazine ErRanolazine | 28 | $2,593 |
| Nebivolol Hcl | 22 | $2,200 |
| Potassium Chloride | 30 | $1,825 |
| Nifedipine ErNifedipine | 48 | $1,725 |
| Carvedilol | 202 | $1,683 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $606 | $271,204238 claims |
| Johnson & JohnsonXarelto | $641 | $84,27766 claims |
| NovartisEntresto | $2,076 | $80,22969 claims |
| Novo NordiskOzempic | $108 | $52,81934 claims |
| Boehringer IngelheimJardiance | $952 | $47,76138 claims |
| AstraZenecaBrilinta, Farxiga | $590 | $42,58961 claims |
| Lilly USA, LLCTrulicity | $128 | $18,94819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Saint Louis
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Alan ZajariasSaint Louis$203K
- Anish ThomasSaint Louis$171K
- Gus TheodosSaint Louis$165K
- Prashanth ThakkerSaint Louis$129K
- Marc SintekSaint Louis$119K
- George KichuraSaint Louis$118K
- Gil VardiSaint Louis$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.